Passage Bio Inc
(NAS:PASG)
$
0.657
-0.0029 (-0.44%)
Market Cap: 40.58 Mil
Enterprise Value: -18.43 Mil
PE Ratio: 0
PB Ratio: 0.56
GF Score: 36/100 Passage Bio Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021 / 03:20PM GMT
Release Date Price:
$14.43
(+2.63%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP
Good morning. Thanks for joining us. I'm Salveen Richter, Biotechnology Analyst at Goldman Sachs. And we're really pleased to have Passage Bio with us today, where we have Bruce Goldsmith, CEO of the company.
Bruce, thanks for joining us.
Bruce A. Goldsmith
Passage Bio, Inc. - CEO, President & Director
Absolutely.
Questions & Answers
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP
To start here, can you remind us of the catalyst path in terms of data for the remainder of 2021 and into 2022 as you look to have first proof-of-concept here across your neurology platform in gene therapy?
Bruce A. Goldsmith
Passage Bio, Inc. - CEO, President & Director
Absolutely. Thanks for the opportunity, and thanks for inviting me today. So yes, the catalysts are really based on the fact that in January of this year, we -- in January, February, we received 3
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot